Recruiting

High-Fiber Diet with DRVd

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT07226609

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

nutrition counseling and coaching

dietary guidelines, research dietitian visit

Questionnaires

Frozen pre-prepared meals

Study Details

Brief summary:

The purpose of the study is to find out whether a dietary intervention can affect treatment response and/or quality of life for people with newly diagnosed multiple myeloma receiving standard induction chemotherapy with daratumumab (or isatuximab), lenalidomide, bortezomib, and dexamethasone (DRVd). The researchers will measure quality of life by having participants complete questionnaires. The study will investigate the effects of diet on quality of life, treatment response, and other disease, microbiome, and immune markers.

Conditions

Multiple Myeloma

Study ID

NCT07226609

Start date

Nov 4, 2025

Status verified date

May, 2026

Completion date

Nov, 2028

Anticipated

Primary completion date

Nov, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Newly diagnosed multiple myeloma
  • Patients must have pathologically confirmed multiple myeloma on bone marrow biopsy with cytogenetics via Florescence in Situ Hybridization (FISH) or SNP array or genomic sequencing report and evaluation of blood myeloma markers (quantitative immunoglobulins, free light chains, serum protein electrophoresis and immunofixation).
  • Age ≥ 18 years
  • Bone marrow involvement
  • Planned for four 28-day cycles of daratumumab (or isatuximab), lenalidomide, bortezomib, dexamethasone (or any other steroid) (DRVd) induction chemotherapy (with once weekly bortezomib day 1, 8, 15 and lenalidomide 21/28 days).
  • All 4 planned drugs initiated by C2D1.
  • Must enroll before C1D21 of induction chemotherapy as study intervention starts at C2D1.
  • Treatment at a site where treating oncologist has capability and plan to send for bone marrow MRD negativity by next generation sequencing at end of 4 cycles (EOI). To be confirmed with local oncologist at enrollment.
  • Treatment at MSK or at a site that uses EPIC for electronic medical records and willing to share records with MSK through EPIC's Care Everywhere or through MSK's shared care network.
  • Enrollment on another trial that allows for 4 cycles of 28-day DRVd is acceptable.
  • Prior dexamethasone treatment is eligible.
  • Patients who have received up to one cycle of cyclophosphamide and/or bortezomib with dexamethasone for disease control are eligible.
  • Able to complete study procedures and visits.
  • Patients on GLP-1 drugs are eligible if it has been started at least 3 months prior to C2D1 DRVd or if it has been started more recently for diabetes mellitus control but not weight loss. If it is medically indicated and started for diabetes mellitus control while on trial they will not be removed/excluded from trial.
  • Participant or caregiver must be able to complete surveys.
  • Baseline 24-hour dietary recall must consume <30 grams dietary fiber per day to be eligible.
  • Patients that already follow a minimally processed (whole food) plant-based diet in the last 3 months are not eligible (ovo-lacto-vegetarian or processed junk food vegan diets are eligible).

Exclusion Criteria:

  • Leptomeningeal/CNS involvement
  • Prior cycles of combination cytotoxic infusion chemotherapy such as VDPACE or DCEP are not eligible.
  • Patients with BMI ≤19 kg/m2 are excluded.
  • If in the opinion of the investigator there maybe any concerns regarding the ability of the patient to complete the study safely or any contraindications.
  • Severe allergy to any legume (such as anaphylactic shock) or allergies to multiple legumes or if cross-contamination is a risk are not eligible.
  • Severe allergies such as anaphylactic shock to peanuts and/or tree nuts, such as cashews are not eligible.
  • Enrollment onto concurrent therapeutic study that requires patient receives treatment other than 4 cycles of DRVd induction as described above.
  • Concurrent weight loss or dietary programs will be ineligible if require a specific diet or weight loss supplements.
  • Plan for prolonged travel during the study that would preclude adherence to prescribed diet. Willingness to comply during travel is not an exclusion.

Study Design

Enrollment

220 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Usual care (UC)

Usual care (UC) While receiving standard induction chemotherapy as part of routine care, participants will have phone calls with a member of the study team every 4 weeks. At the end of standard induction chemotherapy, participants will have a phone call or video call with a dietitian.

experimental: Intervention arm

While receiving standard induction chemotherapy as part of routine care,participants will have a phone call or video call with a dietitian every 2 weeks for 12 weeks and will receive high-fiber plant-based meals for 12 weeks.

Interventions

nutrition counseling and coaching

In addition to individual counseling, patients will be able to join optional group sessions every 2 weeks as well as text message check-ins for survey completion reminders. Patients will receive 12 frozen, fixed pre-made lunch and dinner shipped to their home weekly from Modify Health for 12 weeks.

dietary guidelines, research dietitian visit

Participants will have phone calls with a member of the study team every 4 weeks as well as text message check-ins for survey completion reminders. At the end of standard induction chemotherapy, participants will have a phone call or video call with a dietitian

Questionnaires

Block FFQ survey, EORTC QLQ C30 survey, EORTC MY20 survey, Pre intervention survey, Post intervention survey

Frozen pre-prepared meals

Patients will receive 12 frozen, fixed pre-made lunch and dinner shipped to their home weekly from Modify Health for 12 weeks.

Primary outcome measure

  • Minimal residual disease negative complete response (MRD-CR) rate [ Time Frame: 1 year ]

Central Contacts and Locations

Central contacts

Urvi A Shah, MD, MS

646-608-3713ShahNutrivention@mskcc.org

Carlyn Rose Tan, MD

646-608-3778

Locations

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Recruiting

Basking Ridge, New Jersey, United States, 07920

Contacts

Urvi A Shah, MD, MS

646-608-3713ShahNutrivention@mskcc.org

Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Recruiting

Middletown, New Jersey, United States, 07748

Contacts

Urvi A Shah, MD, MS

646-608-3713ShahNutrivention@mskcc.org

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Recruiting

Montvale, New Jersey, United States, 07645

Contacts

Urvi A Shah, MD, MS

646-608-3713ShahNutrivention@mskcc.org

Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)

Recruiting

Commack, New York, United States, 11725

Contacts

Urvi A Shah, MD, MS

646-608-3713ShahNutrivention@mskcc.org

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Recruiting

Harrison, New York, United States, 10604

Contacts

Urvi A Shah, MD, MS

646-608-3713ShahNutrivention@mskcc.org

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

Recruiting

New York, New York, United States, 10065

Contacts

Urvi A Shah, MD, MS

646-608-3713ShahNutrivention@mskcc.org

Carlyn Rose Tan, MD

646-608-3778

Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Recruiting

Uniondale, New York, United States, 11553

Contacts

Urvi A Shah, MD, MS

646-608-3713ShahNutrivention@mskcc.org

More Information

Sponsor

Memorial Sloan Kettering Cancer Center

Last update posted

May 5, 2026

Last verified

May, 2026

Keywords

  • Dietary Trial
  • Dietary Risk Factors
  • High fiber plant-based diet
  • 25-237

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2026-05-05.